Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 28, 2021

Weekly Subcutaneous Semaglutide for Weight Loss Maintenance in Obese/Overweight Adults

JAMA: The Journal of the American Medical Association


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
JAMA 2021 Apr 13;325(14)1414-1425, D Rubino, N Abrahamsson, M Davies, D Hesse, FL Greenway, C Jensen, I Lingvay, O Mosenzon, J Rosenstock, MA Rubio, G Rudofsky, S Tadayon, TA Wadden, D Dicker, STEP 4 Investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading